Skip to main content
SpringerLink
Log in

Drug-Induced Macular Edema

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Macular edema constitutes a serious pathologic entity of ophthalmology resulting in vision loss with a remarkable impact on the quality of life of patients. It is the final common pathway of various systemic diseases and underlying intraocular conditions, with diabetes mellitus being the most frequent cause. Other causes include venous occlusive disease, intraocular surgery, and inflammatory conditions of the posterior segment of the eye. Macular edema is a recognized side effect of various systemic and local medications and requires special consideration among ophthalmologists and other clinicians. Recently, antidiabetic thiazolidinediones have been implicated in the development of macular edema, and a review of the English literature revealed that other systemically administered drugs like fingolimod, recently approved for relapsing forms of multiple sclerosis, the anticancer agents tamoxifen and the taxanes, as well as niacin and interferons have been reported to cause macular edema. Ophthalmologic pharmaceutical agents, like prostaglandin analogs, epinephrine, timolol, and ophthalmic preparation preservatives have also been reported to cause macular edema as an adverse event. The purpose of this article is to provide a short, balanced overview of the available evidence in this regard. The available data and the possible pathophysiologic mechanisms leading to the development of macular edema are discussed. Possible therapeutic strategies for drug-induced macular edema are also proposed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig.1

Similar content being viewed by others

References

  1. Lobo C, Bernardes R, Faria de Abreu JR, Cunha-Vaz JG. Novel imaging techniques for diabetic macular edema. Doc Ophthalmol. 1999;97:341–7.

    Article  PubMed  CAS  Google Scholar 

  2. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106–18.

    Article  PubMed  Google Scholar 

  3. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association. European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.

    Article  PubMed  CAS  Google Scholar 

  4. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc. 2003;78:1088–91.

    Article  PubMed  CAS  Google Scholar 

  5. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy. 2002;22:924–9.

    Article  PubMed  Google Scholar 

  6. Avandia Package Insert (see adverse reactions section). http://medlibrary.org/lib/rx/meds/rosiglitazone-maleate.

  7. Actos Package Insert. (see adverse reactions section). http://medlibrary.org/lib/rx/meds/actos/page/6/#_ADVERSE_REACTIONS.

  8. Bando Y, Ushiogi Y, Okafuji K, Toya D, Tanaka N, Fujisawa M. Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors. J Int Med Res. 1999;27:53–64.

    PubMed  CAS  Google Scholar 

  9. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003;9:406–16.

    Article  PubMed  Google Scholar 

  10. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol. 2005;123:1273–5.

    Article  PubMed  Google Scholar 

  11. Ryan EH Jr, Han DP, Ramsay RC, Cantrill HL, Bennett SR, Dev S, Williams DF. Diabetic macular edema associated with glitazone use. Retina. 2006;26:562–70.

    Article  PubMed  Google Scholar 

  12. Emoto M, Anno T, Sato Y, Tanabe K, Okuya S, Tanizawa Y, Matsutani A, Oka Y. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patient and its mRNA in 3T3-L1 adipocytes. Diabetes. 2001;50:1166–70.

    Article  PubMed  CAS  Google Scholar 

  13. Oshitari T, Asaumi N, Watanabe M, Kumagai K, Mitamura Y. Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study. Vasc Health Risk Manag. 2008;4:1137–40.

    Article  PubMed  CAS  Google Scholar 

  14. Kendall C, Wooltorton E. Rosiglitazone (Avandia) and macular edema. CMAJ. 2006;174:623.

    Article  PubMed  Google Scholar 

  15. Liazos E, Broadbent DM, Beare N, Kumar N. Spontaneous resolution of diabetic macular oedema after discontinuation of thiazolidenediones. Diabet Med. 2008;25:860–2.

    Article  PubMed  CAS  Google Scholar 

  16. Asensio-Sánchez VM, Asensio-Sánchez MJ, Gómez-Ramírez V. Macular oedema due to rosiglitazone treatment in diabetes mellitus. Arch Soc Esp Oftalmol. 2010;85:246–8.

    PubMed  Google Scholar 

  17. Tatti P, Arrigoni F, Longobardi A, Costanza F, Di Blasi P, Merante D. Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus. Clin Drug Investig. 2008;28:327–32.

    Article  PubMed  CAS  Google Scholar 

  18. Shen LQ, Child A, Weber GM, Folkman J, Aiello LP. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol. 2008;126:793–9.

    Article  PubMed  Google Scholar 

  19. Singh S, Segal JB. Thiazolidinediones and macular edema: comment on “Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes”. Arch Intern Med. 2012;172:1011–3.

    Article  PubMed  CAS  Google Scholar 

  20. Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol. 2009;147(583–586):e1.

    PubMed  Google Scholar 

  21. Ambrosius WT, Danis RP, Goff DC Jr, Greven CM, Gerstein HC, Cohen RM, Riddle MC, Miller ME, Buse JB, Bonds DE, Peterson KA, Rosenberg YD, Perdue LH, Esser BA, Seaquist LA, Felicetta JV, Chew EY, ACCORD Study Group. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol. 2010;128:312–8.

    Article  PubMed  CAS  Google Scholar 

  22. Colucciello M, Ryan E. Macular edema and thiazolidinediones. Arch Ophthalmol. 2010;128:1630–1.

    Article  PubMed  Google Scholar 

  23. Tarbett AK, VanRoekel RC, Howard RS, Vigersky RA. The use of optical coherence tomography to determine the effect of thiazolidinediones on retinal thickness in patients with type 2 diabetes. J Diabetes Sci Technol. 2011;5:945–51.

    PubMed  Google Scholar 

  24. Motola D, Piccinni C, Biagi C, Raschi E, Marra A, Marchesini G, Poluzzi E. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug Saf. 2012;35:315–23.

    Article  PubMed  CAS  Google Scholar 

  25. Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med. 2012;172:1005–11.

    Article  PubMed  CAS  Google Scholar 

  26. Salvadori M, Budde K, Charpentier B, Klempnauer J, Nashan B, Pallardo LM, Eris J, Schena FP, Eisenberger U, Rostaing L, Hmissi A, Aradhye S, FTY720 0124 Study Group. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transpl. 2006;6:2912–21.

    Article  CAS  Google Scholar 

  27. Saab G, Almony A, Blinder KJ, Schuessler R, Brennan DC. Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient. Arch Ophthalmol. 2008;126:140–1.

    Article  PubMed  Google Scholar 

  28. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15.

    Article  PubMed  CAS  Google Scholar 

  29. Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.

    Article  PubMed  CAS  Google Scholar 

  30. Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012;78:672–80.

    Article  PubMed  CAS  Google Scholar 

  31. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha’afi RI, Hla T. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 1999;99:301–12.

    Article  PubMed  CAS  Google Scholar 

  32. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, English D. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest. 2001;108:689–701.

    PubMed  CAS  Google Scholar 

  33. Tauseef M, Kini V, Knezevic N, Brannan M, Ramchandaran R, Fyrst H, Saba J, Vogel SM, Malik AB, Mehta D. Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ Res. 2008;103:1164–72.

    Article  PubMed  CAS  Google Scholar 

  34. Liu L, Cuthbertson F. Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis. Case Rep Med. 2012;2012:134636.

    PubMed  Google Scholar 

  35. Turaka K, Bryan JS. Does fingolimod in multiple sclerosis patients cause macular edema? J Neurol. 2012;259:386–8.

    Article  PubMed  Google Scholar 

  36. Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci. 2012;323:167–72.

    Article  PubMed  CAS  Google Scholar 

  37. Gilenya medication guide—Food and Drug Administration. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM227569.pdf. Accessed 14 Dec 2012.

  38. Eisner A, Luoh SW. Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res. 2011;36:867–85.

    Article  PubMed  CAS  Google Scholar 

  39. Teitelbaum BA, Tresley DJ. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci. 2003;80:277–9.

    Article  PubMed  Google Scholar 

  40. Telander DG, Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol. 2007;22:151–3.

    Article  PubMed  Google Scholar 

  41. Joshi MM, Garretson BR. Paclitaxel maculopathy. Arch Ophthalmol. 2007;125:709–10.

    Article  PubMed  Google Scholar 

  42. Smith SV, Benz MS, Brown DM. Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol. 2008;126:1605–6.

    Article  PubMed  Google Scholar 

  43. Murphy CG, Walsh JB, Hudis CA, Lake D, Theodoulou M. Cystoid macular edema secondary to nab-paclitaxel therapy. J Clin Oncol. 2010;28:e684–7.

    Article  PubMed  Google Scholar 

  44. Baskin DE, Garg SJ. Abraxane-induced cystoid macular edema refractory to concomitant intravenous bevacizumab. Can J Ophthalmol. 2011;46:200–1.

    PubMed  Google Scholar 

  45. Meyer KM, Klink T, Ugurel S, Bröcker EB. Regression of paclitaxel-induced maculopathy with oral acetazolamide. Graefes Arch Clin Exp Ophthalmol. 2012;250:463–4.

    Article  PubMed  Google Scholar 

  46. Georgakopoulos CD, Makri OE, Vasilakis P, Exarchou A. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy. Clin Exp Optom. 2012;95:233–6.

    Article  PubMed  Google Scholar 

  47. Kuznetcova TI, Cech P, Herbort CP. The mystery of angiographically silent macular oedema due to taxanes. Int Ophthalmol. 2012;32:299–304.

    Article  PubMed  Google Scholar 

  48. Ham DS, Lee JE, Kim HW, Yun IH. A case of cystoid macular edema associated with paclitaxel chemotherapy. Korean J Ophthalmol. 2012;26:388–90.

    Article  PubMed  Google Scholar 

  49. Rahman HT, Yeh S, Bergstrom CS. Cystoid macular edema without leakage secondary to nab-paclitaxel (abraxane): clinical experience with intravitreal bevacizumab. J Ocul Pharmacol Ther. 2013;29:360–2.

    Article  PubMed  CAS  Google Scholar 

  50. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.

    Article  PubMed  CAS  Google Scholar 

  51. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep. 1978;62:315–20.

    PubMed  CAS  Google Scholar 

  52. McKeown CA, Swartz M, Blom J, Maggiano JM. Tamoxifen retinopathy. Br J Ophthalmol. 1981;65:177–9.

    Article  PubMed  CAS  Google Scholar 

  53. Gerner EW. Ocular toxicity of tamoxifen. Ann Ophthalmol. 1989;21:420–3.

    PubMed  CAS  Google Scholar 

  54. Griffiths MF. Tamoxifen retinopathy at low dosage. Am J Ophthalmol. 1987;104:185–6.

    PubMed  CAS  Google Scholar 

  55. Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, Gomolin JE, Margolese RG, Mathen MK, Bowman DM, Kaufman DI, Dimitrov NV, Singerman LJ, Bornstein R, Wolmark N. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol. 1998;125:493–501.

    Article  PubMed  CAS  Google Scholar 

  56. Lazzaroni F, Scorolli L, Pizzoleo CF, Savini G, De Nigris A, Giosa F, Meduri RA. Tamoxifen retinopathy: does it really exist? Graefes Arch Clin Exp Ophthalmol. 1998;236:669–73.

    Article  PubMed  CAS  Google Scholar 

  57. Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer. 1992;69:2961–4.

    Article  PubMed  CAS  Google Scholar 

  58. Gualino V, Cohen SY, Delyfer MN, Sahel JA, Gaudric A. Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophthalmol. 2005;140:757–8.

    Article  PubMed  Google Scholar 

  59. Bourla DH, Sarraf D, Schwartz SD. Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. Am J Ophthalmol. 2007;144:126–8.

    Article  PubMed  CAS  Google Scholar 

  60. Bourla DH, Gonzales CR, Mango CW, Moral JN, Wirthlin RS, Schwartz SD. Intravitreous vascular endothelial growth factor (VEGF) inhibitor therapy for tamoxifen induced macular edema. Semin Ophthalmol. 2007;22:87–8.

    Article  PubMed  Google Scholar 

  61. Park SS, Zawadzki RJ, Truong SN, Choi SS, Werner JS. Microcystoid maculopathy associated with tamoxifen use diagnosed by high-resolution fourier-domain optical coherence tomography. Retin Cases Brief Rep. 2009;3:33–5.

    Article  PubMed  Google Scholar 

  62. Chung SE, Kim SW, Chung HW, Kang SW. Estrogen antagonist and development of macular hole. Korean J Ophthalmol. 2010;24:306–9.

    Article  PubMed  Google Scholar 

  63. Cronin BG, Lekich CK, Bourke RD. Tamoxifen therapy conveys increased risk of developing a macular hole. Int Ophthalmol. 2005;26:101–5.

    Article  PubMed  Google Scholar 

  64. Mäenpää H, Mannerström M, Toimela T, Salminen L, Saransaari P, Tähti H. Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells. Pharmacol Toxicol. 2002;91:116–22.

    Article  PubMed  Google Scholar 

  65. Dyer MA, Cepko CL. Control of Müller glial cell proliferation and activation following retinal injury. Nat Neurosci. 2000;3:873–80.

    Article  PubMed  CAS  Google Scholar 

  66. Rahimy E, Sarraf D. Bevacizumab therapy for tamoxifen-induced crystalline retinopathy and severe cystoid macular edema. Arch Ophthalmol. 2012;130:931–2.

    Article  PubMed  Google Scholar 

  67. Mauget-Faÿsse M, Gambrelle J, Quaranta-El Maftouhi M. Optical coherence tomography in tamoxifen retinopathy. Breast Cancer Res Treat. 2006;99:117–8.

    Article  PubMed  CAS  Google Scholar 

  68. Gass JD. Nicotinic acid maculopathy. Am J Ophthalmol. 1973;76:500–10.

    PubMed  CAS  Google Scholar 

  69. Jampol LM. Niacin maculopathy. Ophthalmology. 1988;95:1704–5.

    PubMed  CAS  Google Scholar 

  70. Millay RH, Klein ML, Illingworth DR. Niacin maculopathy. Ophthalmology. 1988;95:930–6.

    PubMed  CAS  Google Scholar 

  71. Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. Br J Ophthalmol. 1995;79:54–6.

    Article  PubMed  CAS  Google Scholar 

  72. Callanan D, Blodi BA, Martin DF. Macular edema associated with nicotinic acid (niacin). JAMA. 1998;3(279):1702.

    Article  Google Scholar 

  73. Spirn MJ, Warren FA, Guyer DR, Klancnik JM, Spaide RF. Optical coherence tomography findings in nicotinic acid maculopathy. Am J Ophthalmol. 2003;135:913–4.

    Article  PubMed  Google Scholar 

  74. Dajani HM, Lauer AK. Optical coherence tomography findings in niacin maculopathy. Can J Ophthalmol. 2006;41:197–200.

    Article  PubMed  Google Scholar 

  75. Davis MJ, Ravage ZB, Packo KH, Arevalo JF, Bernstein PS, Berger AS. Diagnostic and therapeutic challenges. Retina. 2008;28:520–4.

    Article  PubMed  Google Scholar 

  76. Deuter CM, Kötter I, Günaydin I, Stübiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906–13.

    Article  PubMed  CAS  Google Scholar 

  77. Hayasaka S, Nagaki Y, Matsumoto M, Sato S. Interferon associated retinopathy. Br J Ophthalmol. 1998;82:323–5.

    Article  PubMed  CAS  Google Scholar 

  78. Abd El-Badie Mohamed M, Abd-El Azeem Eed K. Retinopathy associated with interferon therapy in patients with hepatitis C virus. Clin Ophthalmol. 2012;6:1341–5.

    Article  PubMed  Google Scholar 

  79. Tokai R, Ikeda T, Miyaura T, Sato K. Interferon-associated retinopathy and cystoid macular oedema. Arch Ophthalmol. 2001;119:1077–9.

    PubMed  CAS  Google Scholar 

  80. Shimura M, Saito T, Yasuda K, Tamai M. Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography. Jpn J Ophthalmol. 2005;49:231–4.

    Article  PubMed  Google Scholar 

  81. Sheth HG, Michaelides M, Siriwardena D. Cystoid macular edema and visual loss as sequelae to interferon alpha treatment of systemic hepatitis C. Indian J Ophthalmol. 2010;58:147–8.

    Article  PubMed  Google Scholar 

  82. Kang HY, Shin MC. Pegylated interferon-associated severe retinopathy in a patient with chronic hepatitis. Korean J Ophthalmol. 2012;26:147–50.

    Article  PubMed  CAS  Google Scholar 

  83. Nagaoka T, Sato E, Takahashi A, Yokohama S, Yoshida A. Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci. 2007;48:368–75.

    Article  PubMed  Google Scholar 

  84. Lalonde RG, Deschênes JG, Seamone C. Zidovudine-induced macular edema. Ann Intern Med. 1991;114:297–8.

    Article  PubMed  CAS  Google Scholar 

  85. Vaudaux JD, Guex-Crosier Y. Rifabutin-induced cystoid macular oedema. J Antimicrob Chemother. 2002;49:421–2.

    Article  PubMed  CAS  Google Scholar 

  86. Smith WM, Reddy MG, Hutcheson KA, Bishop RJ, Sen HN. Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia. J Ophthalmic Inflamm Infect. 2012;2:149–52.

    Article  PubMed  Google Scholar 

  87. Lois N, White M. Acitretin-associated maculopathy. Arch Ophthalmol. 2004;122:928–30.

    Article  PubMed  Google Scholar 

  88. Barak A, Morse LS, Schwab I. Leflunomide (Arava)-induced cystoid macular oedema. Rheumatology (Oxford). 2004;43:246–8.

    Article  CAS  Google Scholar 

  89. Kusumi E, Arakawa A, Kami M, Kato D, Yuji K, Kishi Y, Murashige N, Miyakoshi S, Ueyama J, Morinaga S, Taniguchi S, Muto Y. Visual disturbance due to retinal edema as a complication of imatinib. Leukemia. 2004;18:1138–9.

    Article  PubMed  CAS  Google Scholar 

  90. Masood I, Negi A, Dua HS. Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery. J Cataract Refract Surg. 2005;31:2427–8.

    Article  PubMed  Google Scholar 

  91. Georgalas I, Pavesio C, Ezra E. Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect. Graefes Arch Clin Exp Ophthalmol. 2007;245:1585–6.

    Article  PubMed  Google Scholar 

  92. Magrath GN, Pulido JS, Montero J, Mason C, Wilson J. Cystoid macular edema secondary to fluconazole toxicity. Ocul Immunol Inflamm. 2010;18:472–4.

    Article  PubMed  Google Scholar 

  93. Bussone G, Kaswin G, de Menthon M, Delair E, Brézin AP, Guillevin L. Macular oedema following rituximab infusion in two patients with Wegener’s granulomatosis. Clin Exp Rheumatol. 2010;28:90–2.

    PubMed  Google Scholar 

  94. Iacono P, Battaglia Parodi M, Bandello F. Macular edema associated with hydrochlorothiazide therapy. Br J Ophthalmol. 1025;2011(95):1036–7.

    Google Scholar 

  95. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103:138–47.

    PubMed  CAS  Google Scholar 

  96. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297–304.

    PubMed  CAS  Google Scholar 

  97. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol. 2000;11:94–100.

    Article  PubMed  CAS  Google Scholar 

  98. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol. 1997;124:683–5.

    PubMed  CAS  Google Scholar 

  99. Thorne JE, Maguire AM, Lanciano R. CME and anterior uveitis with latanoprost use. Ophthalmology. 1998;105:1981–3.

    Article  PubMed  CAS  Google Scholar 

  100. Gaddie IB, Bennett DW. Cystoid macular edema associated with the use of latanoprost. J Am Optom Assoc. 1998;69:122–8.

    PubMed  CAS  Google Scholar 

  101. Avakian A, Renier SA, Butler PJ. Adverse effects of latanoprost on patients with medically resistant glaucoma. Arch Ophthalmol. 1998;116:679–80.

    PubMed  CAS  Google Scholar 

  102. Heier JS, Steinert RF, Frederick AR Jr. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol. 1998;116:680–2.

    PubMed  CAS  Google Scholar 

  103. Ayyala RS, Cruz DA, Margo CE, Harman LE, Pautler SE, Misch DM, Mines JA, Richards DW. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol. 1998;126:602–4.

    Article  PubMed  CAS  Google Scholar 

  104. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol. 1998;126:134–5.

    Article  PubMed  CAS  Google Scholar 

  105. Wardrop DR, Wishart PK. Latanoprost and cystoid macular oedema in a pseudophake. Br J Ophthalmol. 1998;82:843–4.

    Article  PubMed  CAS  Google Scholar 

  106. Weisz JM, Bressler NM, Bressler SB, Schachat AP. Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. Ophthalmology. 1999;106:1656–9.

    Article  PubMed  CAS  Google Scholar 

  107. Moroi SE, Gottfredsdottir MS, Schteingart MT, Elner SG, Lee CM, Schertzer RM, Abrams GW, Johnson MW. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology. 1999;106:1024–9.

    Article  PubMed  CAS  Google Scholar 

  108. Halpern DL, Pasquale LR. Cystoid macular edema in aphakia and pseudophakia after use of prostaglandin analogs. Semin Ophthalmol. 2002;17:181–6.

    Article  PubMed  Google Scholar 

  109. Tokunaga T, Kashiwagi K, Saito J, Kobayashi K, Kobori Y, Abe K, Tsukahara S. A case of cystoid macular edema associated with latanoprost ophthalmic solution. Jpn J Ophthalmol. 2002;46:656–9.

    Article  PubMed  Google Scholar 

  110. Watanabe K, Hayasaka S, Hayasaka Y, Nagaki Y, Watanabe K. Cystoid macular edema associated with latanoprost use in a pseudophakic eye with a history of surgical complications. Jpn J Ophthalmol. 2003;47:110–2.

    Article  PubMed  Google Scholar 

  111. Jäger M, Jonas JB. Cystoid macular edema associated with latanoprost therapy in a pseudophakic vitrectomized patient after removal of silicone oil endotamponade. Eur J Ophthalmol. 2003;13:221–2.

    PubMed  Google Scholar 

  112. Ahad MA, McKee HD. Stopping prostaglandin analogues in uneventful cataract surgery. J Cataract Refract Surg. 2004;30:2644–5.

    Article  PubMed  Google Scholar 

  113. Altintaş O, Yüksel N, Karabaş VL, Demirci G. Cystoid macular edema associated with latanoprost after uncomplicated cataract surgery. Eur J Ophthalmol. 2005;15:158–61.

    PubMed  Google Scholar 

  114. Dhingra N, Morgan JE. Pseudophakic cystoid macular oedema: 30 months after latanoprost challenge. Eye (Lond). 2007;21:269–71.

    Article  CAS  Google Scholar 

  115. Ozdemir H, Karacorlu M, Karacorlu SA. Serous detachment of macula in cystoid macular edema associated with latanoprost. Eur J Ophthalmol. 2008;18:1014–6.

    PubMed  CAS  Google Scholar 

  116. Grigoropoulos VG, Emfietzoglou I, Nikolaidis P, Theodossiadis PG, Theodossiadis GP. Cystoid macular oedema within 24 h after a single application of latanoprost. Int Ophthalmol. 2009;29:257–9.

    Article  PubMed  Google Scholar 

  117. Panteleontidis V, Detorakis ET, Pallikaris IG, Tsilimbaris MK. Latanoprost-dependent cystoid macular edema following uncomplicated cataract surgery in pseudoexfoliative eyes. Ophthalmic Surg Lasers Imaging. 2010;9:1–5.

    Google Scholar 

  118. Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002;47:S219.

    Article  PubMed  Google Scholar 

  119. Wand M, Gaudio AR. Cystoid macular edema associated with ocular hypotensive lipids. Am J Ophthalmol. 2002;133:403–5.

    Article  PubMed  Google Scholar 

  120. Esquenazi S. Cystoid macular edema in a pseudophakic patient after switching from latanoprost to BAK-free travoprost. J Ocul Pharmacol Ther. 2007;23:567–70.

    Article  PubMed  CAS  Google Scholar 

  121. Agange N, Mosaed S. Prostaglandin-induced cystoid macular edema following routine cataract extraction. J Ophthalmol. 2010;2010:690707.

    PubMed  Google Scholar 

  122. Matsuura K, Sasaki S, Uotani R. Successful treatment of prostaglandin-induced cystoid macular edema with subtenon triamcinolone. Clin Ophthalmol. 2012;6:2105–8.

    Article  PubMed  CAS  Google Scholar 

  123. Carrillo MM, Nicolela MT. Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost. Am J Ophthalmol. 2004;137:966–8.

    Article  PubMed  Google Scholar 

  124. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105:263–8.

    Article  PubMed  CAS  Google Scholar 

  125. Hoyng PF, Rulo AH, Greve EL, Astin M, Gjötterberg M. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood–retinal barrier integrity: a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol. 1997;41:S83–8.

    Article  PubMed  Google Scholar 

  126. Furuichi M, Chiba T, Abe K, Kogure S, Iijima H, Tsukahara S, Kashiwagi K. Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood–ocular barrier. J Glaucoma. 2001;10:233–6.

    Article  PubMed  CAS  Google Scholar 

  127. Miyake K, Ota I, Maekubo K, Ichihashi S, Miyake S. Latanoprost accelerates disruption of the blood–aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol. 1999;117:34–40.

    Article  PubMed  CAS  Google Scholar 

  128. Lima MC, Paranhos A Jr, Salim S, Honkanen R, Devgan L, Wand M, Gaudio AR, Shields MB. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma. 2000;9:317–21.

    Article  PubMed  CAS  Google Scholar 

  129. Wand M, Gaudio AR, Shields MB. Latanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes. J Cataract Refract Surg. 2001;27:1397–401.

    Article  PubMed  CAS  Google Scholar 

  130. Costagliola C, Del Prete A, Verolino M, Antinozzi P, Fusco R, Parmeggiani F, Mastropasqua L. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients. Graefes Arch Clin Exp Ophthalmol. 2002;240:379–86.

    Article  PubMed  CAS  Google Scholar 

  131. Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP. Blood–aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123:186–92.

    Article  PubMed  CAS  Google Scholar 

  132. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53:S93–105.

    Article  PubMed  Google Scholar 

  133. Wand M, Shields BM. Cystoid macular edema in the era of ocular hypotensive lipids. Am J Ophthalmol. 2002;133:393–7.

    Article  PubMed  Google Scholar 

  134. Mataftsi A, Tsaousis KT, Tsinopoulos IT, Dimitrakos SA. Survey of perioperative prostaglandin analogue administration during cataract surgery in Greece. Int Ophthalmol. 2012;32:97–8.

    Article  PubMed  Google Scholar 

  135. Kolker AE, Becker B. Epinephrine maculopathy. Arch Ophthalmol. 1968;79:552–62.

    Article  PubMed  CAS  Google Scholar 

  136. Michels RG, Maumenee AE. Cystoid macular edema associated with topically applied epinephrine in aphakic eyes. Am J Ophthalmol. 1975;80:379–88.

    PubMed  CAS  Google Scholar 

  137. Mackool RJ, Muldoon T, Fortier A, Nelson D. Epinephrine-induced cystoid macular edema in aphakic eyes. Arch Ophthalmol. 1977;95:791–3.

    Article  PubMed  CAS  Google Scholar 

  138. Obstbaum SA, Galin MA, Poole TA. Topical epinephrine and cystoid macular edema. Ann Ophthalmol. 1976;8:455–8.

    PubMed  CAS  Google Scholar 

  139. Thomas JV, Gragoudas ES, Blair NP, Lapus JV. Correlation of epinephrine use and macular edema in aphakic glaucomatous eyes. Arch Ophthalmol. 1978;96:625–8.

    Article  PubMed  CAS  Google Scholar 

  140. Mehelas TJ, Kollarits CR, Martin WG. Cystoid macular edema presumably induced by dipivefrin hydrochloride (Propine). Am J Ophthalmol. 1982;94:682.

    PubMed  CAS  Google Scholar 

  141. Miyake K, Shirasawa E, Hikita M. Active transport system of prostaglandins: clinical implications and considerations. J Cataract Refract Surg. 1992;18:100–5.

    Article  PubMed  CAS  Google Scholar 

  142. Miyake K, Kayazawa F, Manabe R, Miyake Y. Indomethacin and the epinephrine-induced breakdown of the blood–ocular barrier in rabbits. Invest Ophthalmol Vis Sci. 1987;28:482–6.

    PubMed  CAS  Google Scholar 

  143. Bozkurt E, Yazici AT, Pekel G, Albayrak S, Cakir M, Pekel E, Yilmaz OF. Effect of intracameral epinephrine use on macular thickness after uneventful phacoemulsification. J Cataract Refract Surg. 2010;36:1380–4.

    Article  PubMed  Google Scholar 

  144. Hesse RJ, Swan JL 2nd. Aphakic cystoid macular edema secondary to betaxolol therapy. Ophthalmic Surg. 1988;19:562–4.

    PubMed  CAS  Google Scholar 

  145. Miyake K, Ota I, Ibaraki N, Akura J, Ichihashi S, Shibuya Y, Maekubo K, Miyake S. Enhanced disruption of the blood–aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol. 2001;119:387–94.

    PubMed  CAS  Google Scholar 

  146. Miyake K, Ibaraki N, Goto Y, Oogiya S, Ishigaki J, Ota I, Miyake S. ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy. J Cataract Refract Surg. 2003;29:1800–10.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

No funding was received to assist in the preparation of this review. The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Medical School, University of Patras, Rio, 26504, Patras, Greece

    Olga E. Makri & Constantine D. Georgakopoulos

  2. 1st Department of Ophthalmology, University of Athens Medical School, Athens, Greece

    Ilias Georgalas

Authors
  1. Olga E. Makri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ilias Georgalas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Constantine D. Georgakopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Constantine D. Georgakopoulos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Makri, O.E., Georgalas, I. & Georgakopoulos, C.D. Drug-Induced Macular Edema. Drugs 73, 789–802 (2013). https://doi.org/10.1007/s40265-013-0055-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-013-0055-x

Keywords

Search

Navigation